About Vivo Bio Tech
Vivo Bio Tech is a publicly listed company based in Hyderabad (India) founded in 2004. CRO providing drug development, discovery and biologic research services. Its Indian entity Vivo Bio Tech Limited reported revenue of ₹53.77 Cr. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified.
Company details
Vivo Bio Tech was founded in 2004 and is based in Hyderabad, India, operating as a contract research organization in the pharmaceutical and biotechnology sectors. Services encompass in vitro and in vivo studies, toxicity assessments, pharmacological investigations, and pharmacokineticstoxicokinetics analyses. The biologic research division handles gene synthesis, cloning, recombinant protein expression, purification, and monoclonal antibody production for client needs.
- Headquarters Hyderabad, India
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website vivobio.com
- Social LinkedIn
- Legal Name Vivo Bio Tech Ltd.
- Market Cap₹32.62 Cr
VIVOBIOT · NSE
- Share Price₹12.93
-12.04% today
- Revenue₹53.33 Cr
FY 2025-26 · +14.3% YoY
- EBITDA₹20.84 Cr
Margin 39.1%
- Net Profit−₹1.72 Cr
FY 2025-26 · -145.6% YoY
Associated legal entities of Vivo Bio Tech
Vivo Bio Tech is associated with 4 registered companies on The Company Check; the primary company is Vivo Bio Tech Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Vivo Bio Tech Limited Listed CIN L65993TG1987PLC007163 | Active | 12 Feb 1987 | Hyderabad, Telangana | ₹53.8 Cr | 5 | 7 | View details |
| Vivobio Labs Private Limited CIN U73100TG2009PTC065603 | Active | 23 Oct 2009 | Hyderabad, Telangana | 3 | View details | ||
| Vivobio Consulting Services Private Limited CIN U74999TG2018PTC125356 | Active | 28 Jun 2018 | Hyderabad, Telangana | ₹0.2 Cr | 3 | View details | |
| Vivobio Discovery Services Private Limited CIN U24232TG2009PTC065604 | Active | 23 Oct 2009 | Hyderabad, Telangana | ₹0.1 Cr | 3 | View details |
Board of directors of Vivo Bio Tech Limited (Vivo Bio Tech)
Vivo Bio Tech Limited is the primary company behind Vivo Bio Tech. The boards of the 4 registered companies of Vivo Bio Tech currently have 6 directors; the longest-serving is Kalyan Ram Mangipudi, appointed in 2009. 42 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kalyan Ram Mangipudi DIN 02012580 | Whole-time director | 26 Nov 2009 | 16 yrs 10 mo | Vivo Bio Tech Limited, Vivobio Consulting Services Private Limited, Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited |
| Sankaranarayanan Alangudi DIN 02703392 | Whole-time director | 27 May 2016 | 10 yrs 4 mo | Vivo Bio Tech Limited, Vivobio Consulting Services Private Limited, Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited |
| Sri Kalyan Kompella DIN 03137506 | Whole-time director | 03 Nov 2021 | 4 yrs 11 mo | Vivo Bio Tech Limited |
| Shyam Sunder Tipparaju DIN 07167885 | Director | 31 Aug 2023 | 3 yrs 1 mo | Vivo Bio Tech Limited, Vivobio Consulting Services Private Limited, Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited |
| Priya Rajender Goda DIN 07402785 | Director | 11 Jun 2025 | 1 yr 4 mo | Vivo Bio Tech Limited |
| Satyanarayana Vedula DIN 09070986 | Director | 11 Jun 2025 | 1 yr 4 mo | Vivo Bio Tech Limited |
IPO & Listings of Vivo Bio Tech
Vivo Bio Tech is a publicly listed company on the BSE with ticker symbol VIVOBIOT in India, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Sep 2012
- Listed onBSE: 511509
- Listed entityVivo Bio Tech Ltd.
- Exchange sectorDistribution services
- ISININE380K01017
- Share price₹28.27 (-0.63% on the day) · 2026-05-11
- Market capitalisation₹63.1 Cr
- Price to earnings12.2
- EPS (diluted, trailing year)₹2.32
- Volume (last session)8,173
- Analyst consensusNo rating
Financials of Vivo Bio Tech
Exchange-reported figures of Vivo Bio Tech Limited, the listed company behind Vivo Bio Tech (NSE: VIVOBIOT).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 53.33 | 46.67 | 45.45 | 52.23 | 51.39 | 51.78 | 55.35 |
| Revenue growth | +14.3% | +2.7% | -13.0% | +1.6% | -0.8% | -6.5% | - |
| EBITDA | 20.84 | 20.57 | 21.26 | 21.84 | 16.08 | 17.81 | 12.46 |
| EBITDA margin | +39.1% | +44.1% | +46.8% | +41.8% | +31.3% | +34.4% | +22.5% |
| Profit before tax | 4.80 | 8.80 | 4.06 | 4.62 | 4.46 | 8.63 | 4.24 |
| Net profit | (1.72) | 3.77 | 2.52 | 2.65 | 2.19 | 5.69 | 4.43 |
| Net profit margin | -3.2% | +8.1% | +5.5% | +5.1% | +4.3% | +11.0% | +8.0% |
| EPS (₹) | (0.82) | 4.24 | 1.70 | 1.78 | 1.54 | 4.23 | 3.45 |
| Balance sheet | |||||||
| Total assets | 161 | 133 | 128 | 115 | 115 | 73.96 | 57.80 |
| Net worth | 93.16 | 77.90 | 54.40 | 51.87 | 47.13 | 42.53 | 33.03 |
| Total debt | 67.38 | 54.02 | 73.06 | 62.39 | 67.44 | 30.96 | 24.37 |
| Cash & bank | 1.44 | 1.28 | 1.39 | 1.37 | 1.71 | 1.17 | 1.03 |
| Net working capital | 18.96 | 33.18 | 40.59 | 26.11 | 20.20 | 21.56 | 21.04 |
| Cash flow | |||||||
| Cash from operations | 34.93 | 11.83 | 15.52 | 14.83 | 16.64 | 14.18 | 8.61 |
| Cash from investing | (59.35) | (15.84) | (7.95) | (4.00) | (51.11) | (22.82) | (10.23) |
| Cash from financing | 24.57 | 3.90 | (7.56) | (11.18) | 35.02 | 8.78 | 2.09 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.28 | 14.20 | 13.51 | 13.11 | 12.51 | 12.29 | 12.21 | 12.04 |
| Revenue growth (YoY) | +14.2% | +15.5% | +10.7% | +8.9% | +23.5% | - | - | - |
| Other income | 0.06 | 0.03 | 0.14 | 0.13 | 0.14 | 0.15 | 0.01 | 4.63 |
| EBITDA | 5.05 | 4.45 | 5.49 | 5.41 | 5.49 | 5.01 | 5.54 | 5.60 |
| EBITDA margin | +35.4% | +31.3% | +40.6% | +41.3% | +43.9% | +40.8% | +45.4% | +46.5% |
| Depreciation | 3.53 | 2.75 | 2.66 | 2.57 | 2.64 | 2.25 | 2.25 | 2.29 |
| Interest | 1.24 | 1.48 | 1.40 | 1.47 | 1.50 | 1.68 | 1.84 | 2.06 |
| Profit before tax | 0.34 | 0.25 | 1.57 | 1.50 | 1.49 | 1.23 | 1.46 | 5.88 |
| Tax | 0.15 | 5.41 | 0.32 | 0.64 | 0.14 | 0.18 | 0.64 | 0.63 |
| Net profit | 0.19 | (5.16) | 1.25 | 0.86 | 1.35 | 1.05 | 0.82 | 5.25 |
| EPS (₹) | 0.08 | (2.52) | 0.56 | 0.45 | 0.74 | 0.69 | 0.55 | 3.51 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 52.57 | 46.67 | 44.88 | 51.62 | 51.39 | 51.78 | 55.35 |
| Revenue growth | +12.6% | +4.0% | -13.1% | +0.5% | -0.8% | -6.5% | - |
| EBITDA | 20.62 | 20.85 | 21.26 | 21.82 | 16.08 | 17.80 | 12.46 |
| EBITDA margin | +39.2% | +44.7% | +47.4% | +42.3% | +31.3% | +34.4% | +22.5% |
| Profit before tax | 4.58 | 9.08 | 4.06 | 4.60 | 4.46 | 8.62 | 4.24 |
| Net profit | (1.94) | 4.01 | 2.52 | 2.63 | 2.19 | 5.68 | 4.43 |
| Net profit margin | -3.7% | +8.6% | +5.6% | +5.1% | +4.3% | +11.0% | +8.0% |
| EPS (₹) | (0.93) | 4.41 | 1.69 | 1.77 | 1.54 | 4.24 | 3.45 |
| Balance sheet | |||||||
| Total assets | 158 | 131 | 126 | 113 | 113 | 71.75 | 55.54 |
| Net worth | 93.22 | 78.18 | 54.39 | 51.87 | 47.14 | 42.55 | 33.04 |
| Total debt | 63.92 | 51.80 | 70.83 | 60.17 | 65.24 | 28.73 | 22.09 |
| Cash & bank | 1.30 | 1.21 | 1.32 | 0.99 | 1.47 | 1.10 | 0.99 |
| Net working capital | 18.86 | 34.56 | 41.68 | 27.21 | 21.35 | 22.68 | 22.11 |
| Cash flow | |||||||
| Cash from operations | 36.11 | 11.83 | 15.83 | 14.73 | 16.43 | 14.10 | 7.72 |
| Cash from investing | (59.35) | (15.84) | (7.95) | (4.00) | (51.11) | (22.82) | (7.08) |
| Cash from financing | 23.34 | 3.90 | (7.56) | (11.20) | 35.04 | 8.83 | (0.18) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.14 | 13.77 | 13.37 | 13.02 | 12.42 | 12.29 | 12.21 | 12.04 |
| Revenue growth (YoY) | +13.9% | +12.0% | +9.5% | +8.1% | +22.6% | - | - | - |
| Other income | 0.06 | 0.03 | 0.14 | 0.13 | 0.14 | 0.15 | 0.01 | 4.63 |
| Total expenses | 9.09 | 9.59 | 7.86 | 7.60 | 6.89 | 7.15 | 6.60 | 6.36 |
| EBITDA | 5.05 | 4.18 | 5.51 | 5.42 | 5.53 | 5.14 | 5.61 | 5.68 |
| EBITDA margin | +35.7% | +30.4% | +41.2% | +41.6% | +44.5% | +41.8% | +45.9% | +47.2% |
| Depreciation | 3.53 | 2.75 | 2.66 | 2.57 | 2.64 | 2.25 | 2.25 | 2.29 |
| Interest | 1.24 | 1.48 | 1.40 | 1.47 | 1.50 | 1.68 | 1.84 | 2.06 |
| Profit before tax | 0.34 | (0.02) | 1.59 | 1.51 | 1.53 | 1.36 | 1.53 | 5.96 |
| Tax | 0.15 | 5.41 | 0.32 | 0.64 | 0.14 | 0.18 | 0.64 | 0.63 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.28 | 14.20 | 13.51 | 13.11 | 12.51 | 12.29 | 12.21 | 12.04 |
| Revenue growth (YoY) | +14.2% | +15.5% | +10.7% | +8.9% | +23.5% | - | - | - |
| Other income | 0.06 | 0.03 | 0.14 | 0.13 | 0.14 | 0.15 | 0.01 | 4.63 |
| EBITDA | 5.05 | 4.45 | 5.49 | 5.41 | 5.49 | 5.01 | 5.54 | 5.60 |
| EBITDA margin | +35.4% | +31.3% | +40.6% | +41.3% | +43.9% | +40.8% | +45.4% | +46.5% |
| Depreciation | 3.53 | 2.75 | 2.66 | 2.57 | 2.64 | 2.25 | 2.25 | 2.29 |
| Interest | 1.24 | 1.48 | 1.40 | 1.47 | 1.50 | 1.68 | 1.84 | 2.06 |
| Profit before tax | 0.34 | 0.25 | 1.57 | 1.50 | 1.49 | 1.23 | 1.46 | 5.88 |
| Tax | 0.15 | 5.41 | 0.32 | 0.64 | 0.14 | 0.18 | 0.64 | 0.63 |
| Net profit | 0.19 | (5.16) | 1.25 | 0.86 | 1.35 | 1.05 | 0.82 | 5.25 |
| EPS (₹) | 0.08 | (2.52) | 0.56 | 0.45 | 0.74 | 0.69 | 0.55 | 3.51 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 53.33 | 46.67 | 45.45 | 52.23 | 51.39 | 51.78 | 55.35 |
| Revenue growth | +14.3% | +2.7% | -13.0% | +1.6% | -0.8% | -6.5% | - |
| Other income | 0.44 | 4.80 | 0.04 | 0.04 | 0.10 | 0.08 | 0.05 |
| Total expenses | 32.49 | 26.10 | 24.19 | 30.39 | 35.31 | 33.97 | 42.89 |
| Employee cost | 0.00 | 12.14 | 10.68 | 13.52 | 9.42 | 8.57 | 10.00 |
| EBITDA | 20.84 | 20.57 | 21.26 | 21.84 | 16.08 | 17.81 | 12.46 |
| EBITDA margin | +39.1% | +44.1% | +46.8% | +41.8% | +31.3% | +34.4% | +22.5% |
| Depreciation | 10.63 | 9.02 | 9.29 | 9.27 | 7.45 | 5.59 | 5.17 |
| Interest | 5.85 | 7.55 | 7.95 | 7.99 | 4.27 | 3.67 | 3.10 |
| Profit before tax | 4.80 | 8.80 | 4.06 | 4.62 | 4.46 | 8.63 | 4.24 |
| Tax | 6.52 | 1.51 | 1.54 | 1.97 | 2.27 | 2.94 | (0.19) |
| Net profit | (1.72) | 3.77 | 2.52 | 2.65 | 2.19 | 5.69 | 4.43 |
| Net profit margin | -3.2% | +8.1% | +5.5% | +5.1% | +4.3% | +11.0% | +8.0% |
| EPS (₹) | (0.82) | 4.24 | 1.70 | 1.78 | 1.54 | 4.23 | 3.45 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 22.19 | 17.16 | 14.90 | 14.90 | 14.26 | 13.42 | 12.89 |
| Reserves & surplus | 69.35 | 53.47 | 39.50 | 36.97 | 32.18 | 27.68 | 20.14 |
| Shareholders' funds (net worth) | 93.16 | 77.90 | 54.40 | 51.87 | 47.13 | 42.53 | 33.03 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 55.64 | 51.73 | 67.64 | 59.63 | 62.50 | 28.73 | 20.14 |
| Unsecured loans | 11.74 | 2.29 | 5.42 | 2.76 | 4.94 | 2.23 | 4.23 |
| Total debt | 67.38 | 54.02 | 73.06 | 62.39 | 67.44 | 30.96 | 24.37 |
| Total liabilities | 161 | 133 | 128 | 115 | 115 | 73.96 | 57.80 |
| Assets | |||||||
| Gross block | 204 | 159 | 142 | 141 | 139 | 88.01 | 65.36 |
| Net block | 123 | 88.24 | 80.37 | 88.87 | 95.17 | 52.05 | 34.99 |
| Capital work in progress | 4.81 | 12.84 | 9.21 | 1.90 | 0.87 | 0.32 | 0.15 |
| Investments | 21.91 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 8.15 | 7.79 | 8.77 | 7.97 | 9.81 | 13.28 | 10.58 |
| Sundry debtors | 11.75 | 11.25 | 11.80 | 12.38 | 12.02 | 7.29 | 10.48 |
| Cash & bank balances | 1.44 | 1.28 | 1.39 | 1.37 | 1.71 | 1.17 | 1.03 |
| Loans & advances | 7.08 | 21.61 | 25.28 | 10.06 | 2.48 | 5.35 | 4.83 |
| Total current assets | 28.42 | 41.93 | 47.24 | 31.78 | 26.02 | 27.09 | 26.92 |
| Total current liabilities | 9.46 | 8.75 | 6.65 | 5.67 | 5.82 | 5.53 | 5.88 |
| Net working capital | 18.96 | 33.18 | 40.59 | 26.11 | 20.20 | 21.56 | 21.04 |
| Total assets | 161 | 133 | 128 | 115 | 115 | 73.96 | 57.80 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.28 | 1.39 | 1.37 | 1.71 | 1.17 | 1.03 | 0.56 |
| Net cash from operating activities | 34.93 | 11.83 | 15.52 | 14.83 | 16.64 | 14.18 | 8.61 |
| Net cash from investing activities | (59.35) | (15.84) | (7.95) | (4.00) | (51.11) | (22.82) | (10.23) |
| Net cash from financing activities | 24.57 | 3.90 | (7.56) | (11.18) | 35.02 | 8.78 | 2.09 |
| Net change in cash | 0.15 | (0.11) | 0.01 | (0.34) | 0.55 | 0.14 | 0.47 |
| Closing cash | 1.44 | 1.28 | 1.39 | 1.37 | 1.71 | 1.17 | 1.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +14.3% | +2.7% | -13.0% | +1.6% | -0.8% | -6.5% | - |
| EBITDA growth | +1.3% | -3.3% | -2.7% | +35.8% | -9.7% | +42.9% | - |
| PBT growth | -45.5% | +116.8% | -12.1% | +3.6% | -48.3% | +103.5% | +133.0% |
| Net income growth | -145.6% | +49.6% | -4.9% | +21.0% | -61.5% | +28.4% | - |
| Revenue CAGR (3Y) | +0.7% | -3.2% | -4.3% | -1.9% | -2.7% | +3.3% | +17.5% |
| EBITDA CAGR (3Y) | -1.6% | +8.6% | +6.1% | +20.6% | +19.1% | +17.9% | +17.7% |
| Profitability & leverage | |||||||
| Net income margin | -3.2% | +15.6% | +5.5% | +5.1% | +4.3% | +11.0% | +8.0% |
| Return on capital employed | - | +9.0% | +9.9% | +11.0% | +9.3% | +18.7% | +13.7% |
| Return on net worth | - | +5.7% | +4.8% | +5.4% | +4.9% | +15.0% | +14.7% |
| Debt / equity | - | 0.96 | 1.27 | 1.31 | 1.10 | 0.73 | 0.76 |
| Long-term debt / equity | - | 0.67 | 0.86 | 0.94 | 0.72 | 0.32 | 0.31 |
| Interest cover | 57.30 | 65.37 | 66.42 | 63.56 | 49.48 | 30.03 | 42.52 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.31 | 0.32 | 0.37 | 0.45 | 0.68 | 0.92 |
| Inventory turnover | - | 5.64 | 5.43 | 5.88 | 4.45 | 4.34 | 5.88 |
| Debtors turnover | - | 4.05 | 3.76 | 4.28 | 5.32 | 5.83 | 5.86 |
| EPS (₹) | (0.82) | 4.24 | 1.70 | 1.78 | 1.54 | 4.23 | 3.45 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 41.15 | 36.50 | 34.81 | 32.56 | 30.63 | 25.62 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.14 | 13.77 | 13.37 | 13.02 | 12.42 | 12.29 | 12.21 | 12.04 |
| Revenue growth (YoY) | +13.9% | +12.0% | +9.5% | +8.1% | +22.6% | - | - | - |
| Other income | 0.06 | 0.03 | 0.14 | 0.13 | 0.14 | 0.15 | 0.01 | 4.63 |
| Total expenses | 9.09 | 9.59 | 7.86 | 7.60 | 6.89 | 7.15 | 6.60 | 6.36 |
| EBITDA | 5.05 | 4.18 | 5.51 | 5.42 | 5.53 | 5.14 | 5.61 | 5.68 |
| EBITDA margin | +35.7% | +30.4% | +41.2% | +41.6% | +44.5% | +41.8% | +45.9% | +47.2% |
| Depreciation | 3.53 | 2.75 | 2.66 | 2.57 | 2.64 | 2.25 | 2.25 | 2.29 |
| Interest | 1.24 | 1.48 | 1.40 | 1.47 | 1.50 | 1.68 | 1.84 | 2.06 |
| Profit before tax | 0.34 | (0.02) | 1.59 | 1.51 | 1.53 | 1.36 | 1.53 | 5.96 |
| Tax | 0.15 | 5.41 | 0.32 | 0.64 | 0.14 | 0.18 | 0.64 | 0.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 52.57 | 46.67 | 44.88 | 51.62 | 51.39 | 51.78 | 55.35 |
| Revenue growth | +12.6% | +4.0% | -13.1% | +0.5% | -0.8% | -6.5% | - |
| Other income | 0.44 | 4.80 | 0.04 | 0.04 | 0.09 | 0.08 | 0.05 |
| Total expenses | 31.95 | 25.82 | 23.62 | 29.80 | 35.31 | 33.98 | 42.89 |
| Employee cost | 0.00 | 11.86 | 10.13 | 13.15 | 9.42 | 8.57 | 10.00 |
| EBITDA | 20.62 | 20.85 | 21.26 | 21.82 | 16.08 | 17.80 | 12.46 |
| EBITDA margin | +39.2% | +44.7% | +47.4% | +42.3% | +31.3% | +34.4% | +22.5% |
| Depreciation | 10.63 | 9.02 | 9.29 | 9.27 | 7.44 | 5.59 | 5.17 |
| Interest | 5.85 | 7.55 | 7.95 | 7.99 | 4.27 | 3.67 | 3.10 |
| Profit before tax | 4.58 | 9.08 | 4.06 | 4.60 | 4.46 | 8.62 | 4.24 |
| Tax | 6.52 | 1.51 | 1.54 | 1.97 | 2.27 | 2.94 | (0.19) |
| Net profit | (1.94) | 4.01 | 2.52 | 2.63 | 2.19 | 5.68 | 4.43 |
| Net profit margin | -3.7% | +8.6% | +5.6% | +5.1% | +4.3% | +11.0% | +8.0% |
| EPS (₹) | (0.93) | 4.41 | 1.69 | 1.77 | 1.54 | 4.24 | 3.45 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 22.19 | 17.16 | 14.90 | 14.90 | 14.26 | 13.42 | 12.89 |
| Reserves & surplus | 69.41 | 53.75 | 39.49 | 36.97 | 32.19 | 27.70 | 20.15 |
| Shareholders' funds (net worth) | 93.22 | 78.18 | 54.39 | 51.87 | 47.14 | 42.55 | 33.04 |
| Secured loans | 65.70 | 59.47 | 67.64 | 59.63 | 62.50 | 28.73 | 20.14 |
| Unsecured loans | (1.78) | (7.67) | 3.19 | 0.54 | 2.74 | 0.00 | 1.95 |
| Total debt | 63.92 | 51.80 | 70.83 | 60.17 | 65.24 | 28.73 | 22.09 |
| Total liabilities | 158 | 131 | 126 | 113 | 113 | 71.75 | 55.54 |
| Assets | |||||||
| Gross block | 201 | 156 | 139 | 138 | 135 | 84.65 | 62.00 |
| Net block | 120 | 84.88 | 77.01 | 85.51 | 91.81 | 48.69 | 31.63 |
| Capital work in progress | 4.81 | 12.84 | 9.21 | 1.90 | 0.87 | 0.32 | 0.15 |
| Investments | 21.95 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Inventories | 8.15 | 7.79 | 8.77 | 7.97 | 9.81 | 13.28 | 10.58 |
| Sundry debtors | 11.75 | 11.21 | 11.37 | 12.38 | 12.02 | 7.29 | 10.48 |
| Cash & bank balances | 1.30 | 1.21 | 1.32 | 0.99 | 1.47 | 1.10 | 0.99 |
| Loans & advances | 6.96 | 23.10 | 26.76 | 11.54 | 3.87 | 6.54 | 5.94 |
| Total current assets | 28.16 | 43.31 | 48.22 | 32.88 | 27.17 | 28.21 | 27.99 |
| Total current liabilities | 9.30 | 8.75 | 6.54 | 5.67 | 5.82 | 5.53 | 5.88 |
| Net working capital | 18.86 | 34.56 | 41.68 | 27.21 | 21.35 | 22.68 | 22.11 |
| Total assets | 158 | 131 | 126 | 113 | 113 | 71.75 | 55.54 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.21 | 1.32 | 0.99 | 1.47 | 1.10 | 0.99 | 0.53 |
| Net cash from operating activities | 36.11 | 11.83 | 15.83 | 14.73 | 16.43 | 14.10 | 7.72 |
| Net cash from investing activities | (59.35) | (15.84) | (7.95) | (4.00) | (51.11) | (22.82) | (7.08) |
| Net cash from financing activities | 23.34 | 3.90 | (7.56) | (11.20) | 35.04 | 8.83 | (0.18) |
| Net change in cash | 0.09 | (0.11) | 0.32 | (0.47) | 0.37 | 0.11 | 0.46 |
| Closing cash | 1.30 | 1.21 | 1.32 | 0.99 | 1.47 | 1.10 | 0.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +12.6% | +4.0% | -13.1% | +0.5% | -0.8% | -6.5% | - |
| EBITDA growth | -1.1% | -1.9% | -2.6% | +35.7% | -9.7% | +42.9% | - |
| PBT growth | -49.6% | +123.7% | -11.7% | +3.1% | -48.3% | +103.3% | +133.0% |
| Net income growth | -148.4% | +59.1% | -4.2% | +20.1% | -61.4% | +28.2% | - |
| Revenue CAGR (3Y) | +0.6% | -3.2% | -4.7% | -2.3% | -2.7% | +3.3% | +17.5% |
| EBITDA CAGR (3Y) | -1.9% | +9.1% | +6.1% | +20.5% | +19.1% | +17.9% | +17.7% |
| Profitability & leverage | |||||||
| Net income margin | -3.7% | +16.2% | +5.6% | +5.1% | +4.3% | +11.0% | +8.0% |
| Return on capital employed | - | +9.4% | +10.1% | +11.2% | +9.5% | +19.3% | +14.0% |
| Return on net worth | - | +6.1% | +4.7% | +5.3% | +4.9% | +15.0% | +14.7% |
| Debt / equity | - | 0.93 | 1.23 | 1.27 | 1.05 | 0.67 | 0.73 |
| Long-term debt / equity | - | 0.55 | 0.76 | 0.90 | 0.67 | 0.26 | 0.27 |
| Interest cover | 58.56 | 63.82 | 66.42 | 63.67 | 49.42 | 30.06 | 42.52 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.32 | 0.32 | 0.38 | 0.47 | 0.71 | 0.95 |
| Inventory turnover | - | 5.64 | 5.36 | 5.81 | 4.45 | 4.34 | 5.88 |
| Debtors turnover | - | 4.13 | 3.78 | 4.23 | 5.32 | 5.83 | 5.86 |
| EPS (₹) | (0.93) | 4.41 | 1.69 | 1.77 | 1.54 | 4.24 | 3.45 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 41.32 | 36.50 | 34.81 | 32.57 | 30.64 | 25.63 |
Web traffic of Vivo Bio Tech
The website of Vivo Bio Tech (vivobio.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▲ 16.4% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Vivo Bio Tech (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vivo Bio Tech
Complete news archive for Vivo Bio Tech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vivo Bio Tech
Vivo Bio Tech was founded in 2004.
Vivo Bio Tech is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
The primary company behind Vivo Bio Tech, Vivo Bio Tech Limited, reported revenue of ₹53.77 Cr for FY 2026, up 14% year on year.
Vivo Bio Tech was founded in 2004 and is based in Hyderabad, India, operating as a contract research organization in the pharmaceutical and biotechnology sectors. Services encompass in vitro and in vivo studies, toxicity assessments, pharmacological investigations, and pharmacokineticstoxicokinetics analyses. The biologic research division handles gene synthesis, cloning, recombinant protein expression, purification, and monoclonal antibody production for client needs.
Yes, Vivo Bio Tech is publicly traded on BSE under the ticker symbol VIVOBIOT.
Vivo Bio Tech is associated with 4 legal entities: Vivo Bio Tech Limited, Vivobio Consulting Services Private Limited, Vivobio Labs Private Limited and others.
The legal entities of Vivo Bio Tech currently have 7 directors, including Sri Kalyan Kompella, Sankaranarayanan Alangudi, Kalyan Ram Mangipudi and others.